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Purpose: The root and aerial parts of Boerhaavia diffusa Linn. (Nyctaginaceae) were used in 
Ayurveda for the treatment of diabetes. The present study is aimed at evaluating the 
antidiabetic activity of chloroform extract of Boerhaavia diffusa leaves on chronic 
administration in streptozotocin-induced non-insulin-dependent diabetes mellitus (NIDDM) 
model diabetic rats. 
Methods: The blood glucose lowering activity of the leaf extract was studied in streptozotocin-
induced (65 mg/kg, i.v.) NIDDM model diabetic rats  after oral administration of the extract at 
daily doses of 50, 100 and 200 mg/kg body weight for four weeks and compared with 
glibenclamide. Blood samples were collected from the tail vein before and also at weekly 
intervals for four weeks from the first dose of drug administration and blood glucose was 
analyzed by glucose-oxidase method using a visible spectrophotometer.  
Results: The leaf extract of B. diffusa produced dose-dependent reduction in blood glucose in 
streptozotocin-induced NIDDM rats comparable to that of glibenclamide. The results indicate 
that the reduction in blood glucose produced by the extract is probably through rejuvenation of 
pancreatic β-cells or through extrapancreatic action. 
Conclusion: The chloroform extract of Boerhaavia diffusa has significant antidiabetic activity 
and this supports the traditional usage of the plant by Ayurvedic physicians for the control of 
diabetes. 
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Diabetes mellitus, an endocrine disorder, is 
characterized by hyperglycemia and affects 
a large number of people worldwide. By the 
year 2010, the total number of people 
worldwide with diabetes is projected to 
reach 239 millions1. In modern medicine, no 
satisfactory effective therapy is still available 
to cure diabetes mellitus2. Currently 
available therapeutic options such as dietary 
modification, oral hypoglycemics and insulin 
have limitations of their own in treating non-
insulin dependent diabetes mellitus 
(NIDDM)3-4. Therefore, the search for more 
effective and safer hypoglycemic agents has 
continued to be an area of active research. 
The World Health Organization has 
recommended the evaluation of the 
effectiveness of medicinal plants in condition 
where the conventional allopathic treatment 
of diabetes is not adequate5-6.  
 
In the indigenous Indian system of medicine 
(Ayurveda), many herbal medicines have 
been recommended for the treatment of 
diabetes or ‘madhumeha’ and some of them 
have been experimentally evaluated. 
Boerhaavia diffusa Linn. (Nyctaginaceae) is 
a small perennial creeping herb, commonly 
known as “Red hogweed” and distributed 
widely all over in India, and in many other 
countries.  The root and the whole plant are 
used as an Ayurvedic medicine in India and 
Unani medicine in Arab countries for the 
treatment of diabetes, stress, dyspepsia, 
abdominal pain, inflammation, jaundice, 
enlargement of spleen, congestive heart 
failure and bacterial infections7-11. The plant 
is known to possess anti-inflammatory12-13, 
anticonvulsant14, antifibrinolytic15, diuretic16, 
hepatoprotective17-20 and immunomodu-
latory21-22 activities. It has also been reported 
to be useful in the treatment of 
elephantiasis, night blindness, corneal 
ulcers and nephritic syndrome23-26.  
 
Recently, the aqueous leaf extract of the 
plant has been studied for its antidiabetic 
effect in alloxan-induced diabetic rats27-28.  
The present investigation is aimed at 
evaluating the antidiabetic activity of the 
chloroform extract of the plant leaves on 
chronic treatment of streptozotocin-induced 






Glibenclamide was a generous gift sample 
from Hoechst Pharmaceuticals, Mumbai, 
India. Glucose assay kit was obtained from 
the Diagnostic Division of Dr. Reddy’s 
Laboratories, Hyderabad, while 
streptozotocin was purchased from Sigma-
Aldrich, St. Louis, USA. 
 
Plant Material and Extraction 
 
Fresh leaves of B. diffusa were purchased 
from local traders in Visakhapatnam, India 
and shade dried for about two weeks. The 
leaves were botanically authenticated and a 
voucher specimen has been preserved for 
future reference. The dry leaf powder (3 kg) 
was extracted with chloroform in Soxhlet 
apparatus for 24 hr and the extract was 
evaporated to dryness under vacuum in a 




Adult male Sprague-Dawley rats (National 
Institute of Nutrition, Hyderabad) weighing 
250-300 g were used in the study.  They 
were divided into 6 groups of six each and 
were provided with standard pellet diet 
(Ratan Brothers, Hyderabad) and water  
ad libitum.  All rats were acclimatized to the 
laboratory conditions for at least 10 days 
prior to the experiment and were maintained 
in a well-ventilated animal house with 12-hr 
light and dark cycle.  As appropriate, the 
animals were fed with the standard pellet 
diet throughout the experiment, except for 
12 hr prior to blood collection when only 
water was given.  
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The experimental protocol was been 
approved by the Institutional Animal Ethics 
Committee and by the animal regulatory 
body of the India government (Regd. No. 
516/01/A/CPCSEA). 
 
The rats assigned to groups I to V were 
rendered diabetic by injecting streptozotocin 
(65 mg/kg, i.v.; dissolved in 0.1 M citrate 
buffer; pH 4.5) after a baseline blood 
glucose estimation was done.  After 2 to 3 
days, the condition of diabetes was 
assessed by periodic examination of blood 
glucose using glucose-assay sticks. Only 
animals with stable blood glucose above 
300 mg/dl were selected for the study. 
 
B. diffusa extract, in the form of a 
suspension in 0.1% sodium CMC at daily 
doses of 50, 100 and 200 mg/kg body 
weight, were administered orally to the rats 
in groups I, II & III, respectively for 4 weeks.  
Rats in group IV received a similar treatment 
with glibenclamide (25 µg/kg) daily for 4 
weeks while the rats in groups V and VI 
received 3 ml of 0.1% sodium 
carboxymethylcellulose and were used as 
diabetic and normal controls, respectively. 
 
Collection of Blood and Analytical Procedure 
 
Blood samples were collected before and 
also at weekly intervals for 4 weeks from the 
from the tail vein of the rats from the first 
dose of drug administration.  Glucose-
Oxidase assay method29-30 was used to 
determine the blood glucose. 
 
Data and Statistical Analysis 
 
Data are expressed as means ± standard 
error of means of at least triplicate 
determinations. Statistical analysis was 
carried out using one-way analysis of 
variance (ANOVA) and Dunnett’s t-test.  At 
95% confidence interval p values less than 
0.05 were considered to be significant. 
 
Results and Discussion 
The present study was conducted to study 
the antidiabetic activity of B. diffusa in rats to 
provide scientific evidence for its traditional 
usage in the control of diabetes.  From the 
results obtained, it is obvious that chronic 
administration of B. diffusa extract to 
streptozotocin-induced NIDDM rats 
produced blood glucose reduction in a dose-
dependent manner.  To determine whether 
there was a statistically significant difference 
in hypoglycemia achieved by the three 
doses (50, 100 and 200 mg/kg, p.o.) 
chronically administered, the data were 
compared by using one-way analysis of 
variance and the individual groups were 
compared with control group using Dunnet’s 
t-test.  The extract of B. diffusa produced a 
significant reduction in blood glucose after 1 
 
Table 1: Percentage blood glucose reduction produced by B. diffusa after chronic oral 
administration in streptozotocin-induced NIDDM model rats 
 
Percent Blood Glucose Reduction (n=6)  
Rats Week 1 Week  2 Week  3 Week  4  
Normal Control -9.65 ± 1.20 4.05 ± 0.84 7.58 ± 2.59 -4.36 ± 1.64 
Diabetic Control -10.35 ± 9.81 -15.31 ± 16.58 -18.93 ± 10.02 -20.33 ± 19.35 
Treated with 50 mg/kg of extract 4.34 ± 2.43  9.56 ± 4.66 13.82 ± 8.57* 16.30 ± 4.56 
Treated with 100 mg/kg of extract 10.32 ± 8.08* 18.60 ± 9.89* 24.51 ± 8.24*** 29.98 ± 6.94* 
Treated with 200 mg/kg of extract 25.37 ± 10.50* 28.32 ± 8.68** 33.04 ± 7.13*** 38.63 ± 9.46** 
Treated with 25 µg/kg 
glibenclamide  
66.20 ± 9.58*** 60.60 ± 7.93*** 65.74 ± 8.22*** 59.01 ± 9.89*** 
Values are means ± S.E.M;   n = number of animals;  *p<0.05; **p<0.01;    ***p<0.001.  
Odeniyi & Jaiyeoba., 2004                    Release properties of suppositories 
Trop J Pharm Res, June 2004; 3 (1) 308 
week of treatment and increased 
furthermore at the end of 4th week by 30% 
(p<0.01) and 38.6% (p<0.001) at doses of 
100 and 200 mg/kg body weight, 
respectively although the lowest dose (50 
mg/kg) tested could produced significant 
change only after 3 weeks of treatment 
(Table 1).  Glibenclamide (25 µg/kg, 
administered orally, p.o.) produced a 
significant reduction (p< 001) compared to 
diabetic control at the end of 1st week 
(66.2%). The results obtained in this study 
are in good agreement with those observed 
by previous investigators in alloxan-induced 
diabetic rats27-28. 
 
Streptozotocin, a betacytotoxin induces a 
“chemical diabetes” in a wide variety of 
animal species through a massive 
destruction of β-cells of the islets of 
Langerhans and resulting in reduced 
synthesis and release of insulin32.  It is well 
established that sulphonylureas produce 
hypoglycemia by increasing the secretion of 
insulin from pancreas and by increasing the 
glycogen deposition in the liver33,34. These 
compounds are active in mild streptozotocin-
induced diabetes whereas they are inactive 
in intense streptozotocin diabetes (nearly all 
β-cells have been destroyed). Since our 
results showed that glibenclamide reduced 
blood glucose levels in hyperglycemic 
animals, the state of diabetes is not 
severe35,36.  Streptozotocin-treated animals 
receiving the leaf extract of B. diffusa 
showed rapid normalization of blood glucose 
levels in comparison to control and this 
could be due to the possibility that some β-
cells were still active and were acted upon 
by B. diffusa to exert their insulin releasing 
effect.  This suggests that the mode of 
action of the active ingredients of B. diffusa 
is probably mediated by an enhanced 
secretion of insulin, like sulphonylureas. 
Earlier investigations 27-28 also revealed an 
insulin releasing mechanism by the aqueous 
leaf extract of B. diffusa and lend support for 
the results observed in this study. However, 
the possibility of enhanced tissue glucose 
utilization by B. diffusa cannot be ruled out.  
Further work on fractionation, purification, 
identification of active principle(s) and 
detailed mechanistic evaluation on the 
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